|
1
|
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu M, Zhang W, Ma J, Dai Y, Zhang Q, Liu Q, Yang B and Li G: MicroRNA-139-5p regulates chronic inflammation by suppressing nuclear factor-κB activity to inhibit cell proliferation and invasion in colorectal cancer. Exp Ther Med. 18:4049–4057. 2019.PubMed/NCBI
|
|
3
|
Eberlein A, Takasuga A, Setoguchi K, Pfuhl R, Flisikowski K, Fries R, Klopp N, Fürbass R, Weikard R and Kühn C: Dissection of genetic factors modulating fetal growth in cattle indicates a substantial role of the non-SMC condensin I complex, subunit G (NCAPG) gene. Genetics. 183:951–964. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palou R, Dhanaraman T, Marrakchi R, Pascariu M, Tyers M and D'Amours D: Condensin ATPase motifs contribute differentially to the maintenance of chromosome morphology and genome stability. PLoS Biol. 16:e20039802018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang L, Ren L, Chen H, Pan J, Zhang Z, Kuang X, Chen X, Bao W, Lin C, Zhou Z, et al: NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer. Cell Death Dis. 11:5472020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun DP, Lin CC, Hung ST, Kuang YY, Hseu YC, Fang CL and Lin KY: Aberrant expression of NCAPG is associated with prognosis and progression of gastric cancer. Cancer Manag Res. 12:7837–7846. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Wang H, Han Y, Zhu M, Song Z, Zhan D and Jia J: NCAPG induces cell proliferation in cardia adenocarcinoma via PI3K/AKT signaling pathway. Onco Targets Ther. 13:11315–11326. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arai T, Okato A, Yamada Y, Sugawara S, Kurozumi A, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N: Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC. Cancer Med. 7:1988–2002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, Liao W and Wu L: NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling. Onco Targets Ther. 12:8537–8552. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu T, Dong M, Wang Z, Li H and Li X: Elevated mRNA expression levels of NCAPG are associated with poor prognosis in ovarian cancer. Cancer Manag Res. 12:5773–5786. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xue Y, Li PD, Tang XM, Yan ZH, Xia SS, Tian HP, Liu ZL, Zhou T, Tang XG and Zhang GJ: Cytochrome C oxidase assembly factor 1 homolog predicts poor prognosis and promotes cell proliferation in colorectal cancer by regulating PI3K/AKT signaling. Onco Targets Ther. 13:11505–11516. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grossi I, Salvi A, Baiocchi G, Portolani N and De Petro G: Functional role of microRNA-23b-3p in cancer biology. Microrna. 7:156–166. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xian Z, Hu B, Wang T, Zeng J, Cai J, Zou Q and Zhu P: lncRNA UCA1 contributes to 5-fluorouracil resistance of colorectal cancer cells through miR-23b-3p/ZNF281 axis. Onco Targets Ther. 13:7571–7583. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, et al: Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 34:803–811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang G, Zhou H, Xiao H, Li Y and Zhou T: MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 14:1092014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
LoRusso PM: Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 34:3803–3815. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ai J, Gong C, Wu J, Gao J, Liu W, Liao W and Wu L: MicroRNA-181c suppresses growth and metastasis of hepatocellular carcinoma by modulating NCAPG. Cancer Manag Res. 11:3455–3467. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Narayanankutty A: PI3K/Akt/ mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence. Curr Drug Targets. 20:1217–1226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aoki M and Fujishita T: Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189. 2017.PubMed/NCBI
|
|
23
|
Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015.PubMed/NCBI
|
|
24
|
Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Campos-Viguri GE, Peralta-Zaragoza O, Jiménez-Wences H, Longinos-González AE, Castañón-Sánchez CA, Ramírez-Carrillo M, Camarillo CL, Castañeda-Saucedo E, Jiménez-López MA, Martínez-Carrillo DN and Fernández-Tilapa G: MiR-23b-3p reduces the proliferation, migration and invasion of cervical cancer cell lines via the reduction of c-Met expression. Sci Rep. 10:32562020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Begum S, Hayashi M, Ogawa T, Jabboure FJ, Brait M, Izumchenko E, Tabak S, Ahrendt SA, Westra WH, Koch W, et al: An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. Sci Rep. 5:132362015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou C, Chen Y, He X, Zheng Z and Xue D: Functional implication of exosomal miR-217 and miR-23b-3p in the progression of prostate cancer. Onco Targets Ther. 13:11595–11606. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaman MS, Thamminana S, Shahryari V, Chiyomaru T, Deng G, Saini S, Majid S, Fukuhara S, Chang I, Arora S, et al: Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One. 7:e502032012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Xue H, Zhu Z, Gao J, Zhao M and Ma Z: Expression of serum exosomal miR-23b-3p in non-small cell lung cancer and its diagnostic efficacy. Oncol Lett. 20:302020.PubMed/NCBI
|
|
30
|
Zhang Y, Chen D, Zhang G, Wu X, Zhou L, Lin Y, Ding J, An F and Zhan Q: MicroRNA-23b-3p promotes pancreatic cancer cell tumorigenesis and metastasis via the JAK/PI3K and Akt/NF-κB signaling pathways. Oncol Lett. 20:1602020.PubMed/NCBI
|
|
31
|
Chen D, Wu X, Xia M, Wu F, Ding J, Jiao Y, Zhan Q and An F: Upregulated exosomic miR-23b-3p plays regulatory roles in the progression of pancreatic cancer. Oncol Rep. 38:2182–2188. 2017. View Article : Google Scholar : PubMed/NCBI
|
